Senti Biosciences (SNTI) Stock Is Up Over 100%: What's Happening?

Senti Biosciences Inc SNTI shares are trading higher by 102.6% to $0.56 during Monday’s session after the company was awarded $8 million from the California Institute for Regenerative Medicines, which will support the ongoing development of SENTI-202.

The company says SENTI-202 is an investigational cell therapy for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The ongoing Phase 1 trial aims to provide initial efficacy data by the end of 2024 and durability data in 2025.

Timothy Lu, CEO and Co-Founder of Senti Bio, expressed gratitude for CIRM’s support, highlighting SENTI-202’s potential to improve AML treatment. The trial, enrolling adult patients with specific hematologic malignancies in the US and Australia, evaluates two dose levels of SENTI-202 cells administered in cycles after disease-specific conditioning.

Read Also: What’s Going On With GameStop Stock Monday?

Is SNTI A Good Stock To Buy?

An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like Senti Biosciences‘s page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.

These are known as capital allocation programs. Senti Biosciences SNTI does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.

For example, if you're looking to earn an annualized return of 14.97%, you'll need to buy a share of Global Net Lease by the Jul. 11, 2024. Once done, you can expect to receive a nominal payout of $0.28 on Jul. 16, 2024.

Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on Senti Biosciences will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.

According to data from Benzinga Pro, SNTI has a 52-week high of $1.09 and a 52-week low of $0.21.